ExploreWatchlistsPricing
  1. JP-listed companies
  2. HISAMITSU PHARMACEUTICAL CO.,INC.
  3. Financials
  4. Revenue

HISAMITSU PHARMACEUTICAL CO.,INC. (4530)

Market cap
¥514.7B
P/E ratio
19.9x
Hisamitsu Pharmaceutical manufactures and sells over-the-counter medications like allergy treatments, operating globally through subsidiaries in the US, Europe, and Asia.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRevenue (Million JPY)YoY (%)
Feb 28, 2026163,024+4.50%
Feb 28, 2025156,006+10.09%
Feb 29, 2024141,706+10.42%
Feb 28, 2023128,330+6.77%
Feb 28, 2022120,193+4.96%
Feb 28, 2021114,510-18.78%
Feb 29, 2020140,992-1.68%
Feb 28, 2019143,408-3.02%
Feb 28, 2018147,870+1.33%
Feb 28, 2017145,925-9.84%
Feb 29, 2016161,852+3.26%
Feb 28, 2015156,743+4.05%
Feb 28, 2014150,635+5.51%
Feb 28, 2013142,772+3.61%
Feb 29, 2012137,794

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat